These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 23062239)

  • 1. MIA-QSAR modeling of the anti-HIV-1 protease activities and cytotoxicities of ritonavir analogs.
    Silva DG; Freitas MP
    Curr Drug Saf; 2012 Sep; 7(4):269-81. PubMed ID: 23062239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative structure-activity relationship of some HIV-1 protease inhibitors: a Fujita-Ban type analysis.
    Mekapati SB; Sivakumar R; Gupta SP
    J Enzyme Inhib; 2001; 16(3):185-97. PubMed ID: 11697040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of selenazole-substituted ritonavir analogs.
    Qiao J; Zhao C; Liu J; Du Y
    Bioorg Med Chem Lett; 2018 Aug; 28(14):2379-2381. PubMed ID: 29934245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atazanavir/ritonavir: a review of its use in HIV therapy.
    von Hentig N
    Drugs Today (Barc); 2008 Feb; 44(2):103-32. PubMed ID: 18389089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
    Arvieux C; Tribut O
    Drugs; 2005; 65(5):633-59. PubMed ID: 15748098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrating Multiple Receptor Conformation Docking and Multi Dimensional QSAR for Enhancing Accuracy of Binding Affinity Prediction.
    Radhika V; Jaraf HA; Kanth SS; Vijjulatha M
    Curr Comput Aided Drug Des; 2017; 13(2):127-142. PubMed ID: 28103770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Finding the structural requirements of diverse HIV-1 protease inhibitors using multiple QSAR modelling for lead identification.
    Halder AK
    SAR QSAR Environ Res; 2018 Nov; 29(11):911-933. PubMed ID: 30332922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lopinavir/ritonavir: appraisal of its use in HIV therapy.
    von Hentig N
    Drugs Today (Barc); 2007 Apr; 43(4):221-47. PubMed ID: 17460785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The recent application of 3D-QSAR and docking studies to novel HIV-protease inhibitor drug discovery.
    Olotu FA; Agoni C; Soremekun O; Soliman MES
    Expert Opin Drug Discov; 2020 Sep; 15(9):1095-1110. PubMed ID: 32692273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validated predictive QSAR modeling of N-aryl-oxazolidinone-5-carboxamides for anti-HIV protease activity.
    Halder AK; Jha T
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6082-7. PubMed ID: 20832304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine).
    Arribas JR
    Curr Opin HIV AIDS; 2009 Nov; 4(6):507-12. PubMed ID: 20048718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ritonavir (Norvir).
    Res Initiat Treat Action; 2000 Mar; 6(1):26-7. PubMed ID: 11708183
    [No Abstract]   [Full Text] [Related]  

  • 13. Development of anti-HIV activity models of lysine sulfonamide analogs: a QSAR perspective.
    Muthukumaran R; Sangeetha B; Amutha R; Mathur PP
    Curr Comput Aided Drug Des; 2012 Mar; 8(1):70-82. PubMed ID: 21999609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative structure-activity relationship studies on 1-aryl-tetrahydroisoquinoline analogs as active anti-HIV agents.
    Chen KX; Xie HY; Li ZG; Gao JR
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5381-6. PubMed ID: 18835162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoparticle-in-microparticle oral drug delivery system of a clinically relevant darunavir/ritonavir antiretroviral combination.
    Augustine R; Ashkenazi DL; Arzi RS; Zlobin V; Shofti R; Sosnik A
    Acta Biomater; 2018 Jul; 74():344-359. PubMed ID: 29723705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3D-QSAR CoMFA/CoMSIA models based on theoretical active conformers of HOE/BAY-793 analogs derived from HIV-1 protease inhibitor complexes.
    da Cunha EF; Sippl W; de Castro Ramalho T; Ceva Antunes OA; de Alencastro RB; Albuquerque MG
    Eur J Med Chem; 2009 Nov; 44(11):4344-52. PubMed ID: 19616874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oximinoarylsulfonamides as potent HIV protease inhibitors.
    Yeung CM; Klein LL; Flentge CA; Randolph JT; Zhao C; Sun M; Dekhtyar T; Stoll VS; Kempf DJ
    Bioorg Med Chem Lett; 2005 May; 15(9):2275-8. PubMed ID: 15837308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lopinavir-Ritonavir: a new protease inhibitor.
    Mangum EM; Graham KK
    Pharmacotherapy; 2001 Nov; 21(11):1352-63. PubMed ID: 11714208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The crystal structure of protease Sapp1p from Candida parapsilosis in complex with the HIV protease inhibitor ritonavir.
    Dostál J; Brynda J; Hrušková-Heidingsfeldová O; Pachl P; Pichová I; Rezáčová P
    J Enzyme Inhib Med Chem; 2012 Feb; 27(1):160-5. PubMed ID: 22146051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. QSAR studies on HIV-1 protease inhibitors using non-linearly transformed descriptors.
    Saranya N; Selvaraj S
    Curr Comput Aided Drug Des; 2012 Mar; 8(1):10-49. PubMed ID: 21999608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.